Research Analysts Set Expectations for Immunic Q1 Earnings

Immunic, Inc. (NASDAQ:IMUX) – William Blair issued their Q1 2025 earnings per share estimates for Immunic in a note issued to investors on Wednesday, April 30th. William Blair analyst M. Minter anticipates that the company will post earnings per share of ($0.25) for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share. William Blair also issued estimates for Immunic’s Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.22) EPS and FY2029 earnings at $1.05 EPS.

Several other equities research analysts have also weighed in on the stock. StockNews.com lowered shares of Immunic from a “hold” rating to a “sell” rating in a report on Thursday, March 20th. B. Riley restated a “buy” rating and issued a $6.00 price objective on shares of Immunic in a research report on Wednesday, April 16th. D. Boral Capital reiterated a “buy” rating and set a $17.00 target price on shares of Immunic in a report on Wednesday. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Immunic in a report on Thursday. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $13.20.

Immunic Price Performance

Shares of NASDAQ:IMUX opened at $1.17 on Friday. The firm’s 50 day simple moving average is $1.08 and its 200 day simple moving average is $1.12. Immunic has a fifty-two week low of $0.83 and a fifty-two week high of $2.11. The company has a market capitalization of $112.11 million, a price-to-earnings ratio of -0.95 and a beta of 1.91.

Hedge Funds Weigh In On Immunic

A number of large investors have recently added to or reduced their stakes in IMUX. Millennium Management LLC lifted its stake in Immunic by 480.6% in the 4th quarter. Millennium Management LLC now owns 579,683 shares of the company’s stock valued at $580,000 after acquiring an additional 479,846 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Immunic by 45.6% during the 4th quarter. Renaissance Technologies LLC now owns 566,623 shares of the company’s stock worth $567,000 after acquiring an additional 177,542 shares in the last quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Immunic by 90.0% in the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 204,579 shares of the company’s stock valued at $205,000 after purchasing an additional 96,894 shares during the last quarter. Barclays PLC bought a new stake in shares of Immunic in the fourth quarter worth $84,000. Finally, HB Wealth Management LLC bought a new stake in shares of Immunic in the fourth quarter worth $81,000. Institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.